Search

Your search keyword '"Peters, Ron J.G."' showing total 204 results
Start Over Author "Peters, Ron J.G."
204 results on '"Peters, Ron J.G."'

5. Patients' preferences for secondary prevention following a coronary event

Author

van Trier, Tinka J., Jørstad, Harald T., Scholte op Reimer, Wilma J.M., Sunamura, Madoka, ter Hoeve, Nienke, Aernout Somsen, G., Peters, Ron J.G., Snaterse, Marjolein, van Trier, Tinka J., Jørstad, Harald T., Scholte op Reimer, Wilma J.M., Sunamura, Madoka, ter Hoeve, Nienke, Aernout Somsen, G., Peters, Ron J.G., and Snaterse, Marjolein

Abstract

Objective:Despite clear evidence on the effectiveness of secondary prevention, patients with coronary artery disease frequently fail to reach guideline-based risk factor targets. Integrating patients’ preferences into treatment decisions has been recommended to reduce this gap. However, this requires knowledge about patient treatment preferences. Therefore, through a survey study, we aimed to explore which risk factors patients self-perceived, prioritised for improvement, and needed support with after a recent hospitalisation for coronary heart disease. Methods: A digital questionnaire was presented to patients > 18 years recently discharged (≤3 months) from an acute coronary care unit in the Netherlands (Europe). Patients could select from eight cardiovascular risk factors that they (1) self-perceived, (2) prioritised for improvement, and (3) needed support to improve. Patients’ perceived risk factors were compared to those documented in the medical records. Results: Respondents (N = 254, 26 % women), mean age 64 (SD 10) years, identified ‘physical inactivity’ more frequently than their medical records (140 patients vs. 91 records, p < 0.001), while three other risk factors were reported with equal and four with lower frequency. ‘Physical inactivity’, ‘overweight’ and ‘stress’ were most frequently prioritised for improvement (82 %, 88 % and 78 %) and professional support (64 %, 50 % and 58 %), with 87 % preferring lifestyle optimisation if this would reduce drug use. Conclusions: Patients with a recent coronary event show significant disparities in identifying risk factors compared to their medical records. They tend to prefer improving lifestyle- over drug-modifiable risk factors, particularly physical inactivity, overweight and stress, and indicate the need for support in improving these factors.

Published
2024

11. Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

Author

van Trier, Tinka J., Snaterse, Marjolein, Hageman, Steven H.J., Ter Hoeve, Nienke, Sunamura, Madoka, Moll van Charante, Eric P., Galenkamp, Henrike, Deckers, Jaap W., Martens, Fabrice M.A.C., Visseren, Frank L.J., Scholte Op Reimer, Wilma J.M., Peters, Ron J.G., Jørstad, Harald T., van Trier, Tinka J., Snaterse, Marjolein, Hageman, Steven H.J., Ter Hoeve, Nienke, Sunamura, Madoka, Moll van Charante, Eric P., Galenkamp, Henrike, Deckers, Jaap W., Martens, Fabrice M.A.C., Visseren, Frank L.J., Scholte Op Reimer, Wilma J.M., Peters, Ron J.G., and Jørstad, Harald T.

Abstract

BACKGROUND: Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control. AIMS: This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event. METHODS AND RESULTS: Pooled data from six studies are as follows: RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged ≥45 years at ≥6 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0-1.8) after index event, 10-year risk was median (IQR) 20% (15-27%) and lifetime risk 54% (47-63%). Whereas 70% used conventional medication, 82% had ≥1 drug-modifiable risk factor not on target. Furthermore, 91% had ≥1 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4-8%) and of lifetime risk to 20% (15-27%) and a median (IQR) gain of 7.3 (5.4-10.4) atherosclerotic cardiovascular disease event-free years. CONCLUSIONS: Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime.

Published
2023

12. Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

Author

Interne Geneeskunde Vasculaire, Circulatory Health, van Trier, Tinka J., Snaterse, Marjolein, Hageman, Steven H.J., Ter Hoeve, Nienke, Sunamura, Madoka, Moll van Charante, Eric P., Galenkamp, Henrike, Deckers, Jaap W., Martens, Fabrice M.A.C., Visseren, Frank L.J., Scholte Op Reimer, Wilma J.M., Peters, Ron J.G., Jørstad, Harald T., Interne Geneeskunde Vasculaire, Circulatory Health, van Trier, Tinka J., Snaterse, Marjolein, Hageman, Steven H.J., Ter Hoeve, Nienke, Sunamura, Madoka, Moll van Charante, Eric P., Galenkamp, Henrike, Deckers, Jaap W., Martens, Fabrice M.A.C., Visseren, Frank L.J., Scholte Op Reimer, Wilma J.M., Peters, Ron J.G., and Jørstad, Harald T.

Published
2023

14. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics

Author

Lonn, Eva, Bosch, Jackie, Pogue, Janice, Avezum, Alvaro, Chazova, Irina, Dans, Antonio, Diaz, Rafael, Fodor, George J., Held, Claes, Jansky, Petr, Keltai, Matyas, Keltai, Katalin, Kunti, Kamlesh, Kim, Jae-Hyung, Leiter, Lawrence, Lewis, Basil, Liu, Lisheng, Lopez-Jaramillo, Patricio, Pais, Prem, Parkhomenko, Alexandr, Peters, Ron J.G., Piegas, Leopoldo S., Reid, Christopher M., Sliwa, Karen, Toff, William D., Varigos, John, Xavier, Denis, Yusoff, Khalid, Zhu, Jun, Dagenais, Gilles, and Yusuf, Salim

Published
2016
Full Text
View/download PDF

18. Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention: A Cohort Study in ST-Segment Elevation Myocardial Infarction and Comprehensive Meta-analysis

Author

Kikkert, Wouter J., Delewi, Ronak, Ouweneel, Dagmar M., van Nes, Sophie H., Vis, Marije M., Baan, Jan, Jr., Koch, Karel T., Dangas, George D., Mehran, Roxana, de Winter, Robbert J., Peters, Ron J.G., Piek, Jan J., Tijssen, Jan G.P., and Henriques, Jose P.S.

Published
2014
Full Text
View/download PDF

19. Sarcopenia and its relation to protein intake across older ethnic populations in the Netherlands: the HELIUS study

Author

Dorhout, Berber G., Overdevest, Elvera, Tieland, Michael, Nicolaou, Mary, Weijs, Peter J.M., Snijder, Marieke B., Peters, Ron J.G., Van Valkengoed, Irene G.M., Haveman-Nies, Annemien, De Groot, Lisette C.P.G.M., Dorhout, Berber G., Overdevest, Elvera, Tieland, Michael, Nicolaou, Mary, Weijs, Peter J.M., Snijder, Marieke B., Peters, Ron J.G., Van Valkengoed, Irene G.M., Haveman-Nies, Annemien, and De Groot, Lisette C.P.G.M.

Abstract

Objective: To examine the prevalence of sarcopenia and its association with protein intake in men and women in a multi-ethnic population.Design: We used cross-sectional data from the HELIUS (Healthy Life in an Urban Setting) study, which includes nearly 25,000 participants (aged 18–70 years) of Dutch, South-Asian Surinamese, African Surinamese, Turkish, Moroccan, and Ghanaian ethnic origin. For the current study, we included 5161 individuals aged 55 years and older. Sarcopenia was defined according to the EWGSOP2. In a subsample (N = 1371), protein intake was measured using ethnic-specific Food Frequency Questionnaires. Descriptive analyses were performed to study sarcopenia prevalence across ethnic groups in men and women, and logistic regression analyses were used to study associations between protein intake and sarcopenia.Results: Sarcopenia prevalence was found to be sex- and ethnic-specific, varying from 29.8% in Turkish to 61.3% in South-Asian Surinamese men and ranging from 2.4% in Turkish up to 30.5% in South-Asian Surinamese women. Higher protein intake was associated with a 4% lower odds of sarcopenia in the subsample (OR = 0.96, 95%-CI: 0.92–0.99) and across ethnic groups, being only significant in the South-Asian Surinamese group.Conclusion: Ethnic differences in the prevalence of sarcopenia and its association with protein intake suggest the need to target specific ethnic groups for prevention or treatment of sarcopenia.

Published
2022

20. Impact of a Patient’s Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making

Author

Interne Geneeskunde Vasculaire, Unit Opleiding Aios, Circulatory Health, MS Interne Geneeskunde, de Vries, Tamar I., Stam-Slob, Manon C., Peters, Ron J.G., van der Graaf, Yolanda, Westerink, Jan, Visseren, Frank L.J., Interne Geneeskunde Vasculaire, Unit Opleiding Aios, Circulatory Health, MS Interne Geneeskunde, de Vries, Tamar I., Stam-Slob, Manon C., Peters, Ron J.G., van der Graaf, Yolanda, Westerink, Jan, and Visseren, Frank L.J.

Published
2022

23. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

Author

Yusuf, Salim, Lonn, Eva, Pais, Prem, Bosch, Jackie, López-Jaramillo, Patricio, Zhu, Jun, Xavier, Denis, Avezum, Alvaro, Leiter, Lawrence A., Piegas, Leopoldo S., Parkhomenko, Alexander, Keltai, Matyas, Keltai, Katalin, Sliwa, Karen, Chazova, Irina, Peters, Ron J.G., Held, Claes, Yusoff, Khalid, Lewis, Basil S., Jansky, Petr, Khunti, Kamlesh, Toff, William D., Reid, Christopher M., Varigos, John, Accini, Jose L., McKelvie, Robert, Pogue, Janice, Jung, Hyejung, Liu, Lisheng, Diaz, Rafael, Dans, Antonio, and Dagenais, Gilles

Published
2016
Full Text
View/download PDF

24. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Author

Lonn, Eva M., Bosch, Jackie, López-Jaramillo, Patricio, Zhu, Jun, Liu, Lisheng, Pais, Prem, Diaz, Rafael, Xavier, Denis, Sliwa, Karen, Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S., Keltai, Katalin, Keltai, Matyas, Chazova, Irina, Peters, Ron J.G., Held, Claes, Yusoff, Khalid, Lewis, Basil S., Jansky, Petr, Parkhomenko, Alexander, Khunti, Kamlesh, Toff, William D., Reid, Christopher M., Varigos, John, Leiter, Lawrence A., Molina, Dora I., McKelvie, Robert, Pogue, Janice, Wilkinson, Joanne, Jung, Hyejung, Dagenais, Gilles, and Yusuf, Salim

Published
2016
Full Text
View/download PDF

25. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Author

Yusuf, Salim, Bosch, Jackie, Dagenais, Gilles, Zhu, Jun, Xavier, Denis, Liu, Lisheng, Pais, Prem, López-Jaramillo, Patricio, Leiter, Lawrence A., Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S., Parkhomenko, Alexander, Keltai, Katalin, Keltai, Matyas, Sliwa, Karen, Peters, Ron J.G., Held, Claes, Chazova, Irina, Yusoff, Khalid, Lewis, Basil S., Jansky, Petr, Khunti, Kamlesh, Toff, William D., Reid, Christopher M., Varigos, John, Sanchez-Vallejo, Gregorio, McKelvie, Robert, Pogue, Janice, Jung, Hyejung, Gao, Peggy, Diaz, Rafael, and Lonn, Eva

Published
2016
Full Text
View/download PDF

34. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

Author

Lewis, Basil S., Mehta, Shamir R., Fox, Keith A.A., Halon, David A., Zhao, Feng, Peters, Ron J.G., Keltai, Matyas, Budaj, Andrzej, and Yusuf, Salim

Subjects
Coronary heart disease -- Drug therapy, Drug therapy, Combination -- Research, Transluminal angioplasty -- Research, Blood platelets -- Aggregation, Blood platelets -- Research, Health
Published
2005

37. Randomized comparision of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: Results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis)

Author

Peters, Ron J.G., Spickler, William, Theroux, Pierre, White, Harvey, Gibson, Michael, Molhoek, Peter G., Anderson, H. Vernon, Weitz, Jeffrey I., Hirsh, Jack, and Weaver, W. Douglas

Subjects
Heart attack -- Drug therapy, Anticoagulants (Medicine) -- Evaluation, Health
Published
2001

45. Acute coronary syndromes without ST segment elevation

Author

Peters, Ron J.G., Mehta, Shamir, and Yusuf, Salim

Subjects
Coronary heart disease -- Diagnosis, Coronary heart disease -- Care and treatment, Cardiac patients -- Care and treatment, Practice guidelines (Medicine)
Published
2007

48. Grenzen aan de behandeling van hypertensie

Author

Kalkman, Deborah N., Brouwer, Tom F., Spiering, Wilko, Peters, Ron J.G., Van Den Born, Bert Jan H., Cardiology, Graduate School, ACS - Heart failure & arrhythmias, ACS - Atherosclerosis & ischemic syndromes, and Vascular Medicine

Subjects
Medicine(all), Journal Article, English Abstract
Abstract

According to the 2011 Dutch guideline on Cardiovascular risk management 1 in 5 hypertensive patients are eligible for blood pressure lowering treatment. The Dutch guideline recommends striving for a systolic blood pressure (SBP) of < 140 mmHg in adult patients who have no cardiovascular disease or diabetes mellitus, while the recent American guideline now recommends an SBP target value of < 130 mmHg for all adult patients. An important reason for using a stricter SBP target value are the results of randomised studies and meta-analyses that looked at the effect of intensive antihypertensive therapy on the risk of mortality and cardiovascular disease. Based on the literature, there appears to be sufficient evidence that intensive antihypertensive therapy (SBP target value of < 130 mmHg) is useful in patients with cardiovascular disease and in patients with high cardiovascular risk. Currently, there is insufficient evidence that intensive antihypertensive therapy is useful in patients who have diabetes mellitus or who are over 80 years old.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results